Stagnitti MN. Trends in antipsychotics purchases and expenses for the U.S. civilian noninstitutionalized population, 1997 and 2007. Statistical Brief #275. Agency for Healthcare Research and Quality, Rockville, MD. 2010.

Ahrnsbra R, Stagnitti MN. Comparision of antidepressant and antipsychotic utilization and expenditures in the U.S. civilian noninstitutionalized population, 2013 and 2018. Statistical Brief #534. Agency for Healthcare Research and Quality, Rockville, MD. 2021.

Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138:18–28.

Article  PubMed  PubMed Central  Google Scholar 

Dilks S, Xavier RM, Kelly C, Johnson J. Implications of antipsychotic use: antipsychotic-induced movement disorders, with a focus on tardive dyskinesia. Nurs Clin N Am. 2019;54:595–608.

Article  Google Scholar 

Muhlbauer V, Mohler R, Dichter MN, Zuidema SU, Kopke S, Luijendijk HJ. Antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia. Cochrane Database Syst Rev. 2021;12:CD013304.

PubMed  Google Scholar 

Devanand DP. Management of neuropsychiatric symptoms in dementia. Curr Opin Neurol. 2023;36:498–503.

Article  CAS  PubMed  Google Scholar 

Iversen TSJ, Steen NE, Dieset I, Hope S, Mørch R, Gardsjord ES, et al. Side effect burden of antipsychotic drugs in real life - Impact of gender and polypharmacy. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:263–71.

Article  CAS  PubMed  Google Scholar 

Meyer JM, Correll CU. Increased metabolic potential, efficacy, and safety of emerging treatments in schizophrenia. CNS Drugs. 2023;37:545–70.

Article  PubMed  PubMed Central  Google Scholar 

Hauser RA, Meyer JM, Factor SA, Comella CL, Tanner CM, Xavier RM, et al. Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectr. 2022;27:208–17.

Article  PubMed  Google Scholar 

Chepke C, Benning B, Cicero S, Hull M, Giraldo E, Yeaw J, et al. Investigating real-world benztropine usage patterns in movement disorders: claims analysis and health care provider survey results. Prim Care Companion CNS Disord. 2023;25:22m03472.

Schatzberg AF, Nemeroff CB, American Psychiatric Association. The American Psychiatric Association Publishing textbook of psychopharmacology. 5th ed. Arlington: American Psychiatric Association Publishing; 2017.

Book  Google Scholar 

Yohn SE, Weiden PJ, Felder CC, Stahl SM. Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic. Trends Pharmacol Sci. 2022;43:1098–112.

Article  CAS  PubMed  Google Scholar 

Ho TNT, Abraham N, Lewis RJ. Structure-function of neuronal nicotinic acetylcholine receptor inhibitors derived from natural toxins. Front Neurosci. 2020;14: 609005.

Article  PubMed  PubMed Central  Google Scholar 

Brocks DR. Anticholinergic drugs used in Parkinson’s disease: an overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci. 1999;2:39–46.

CAS  PubMed  Google Scholar 

Lester DB, Rogers TD, Blaha CD. Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther. 2010;16:137–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ztaou S, Amalric M. Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson’s disease. Neurochem Int. 2019;126:1–10.

Article  ADS  CAS  PubMed  Google Scholar 

Paz RM, Murer MG. Mechanisms of antiparkinsonian anticholinergic therapy revisited. Neuroscience. 2021;467:201–17.

Article  CAS  PubMed  Google Scholar 

Ward KM, Citrome L. Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia - Key differences in pathophysiology and clinical management. Neurol Ther. 2018;7:233–48.

Article  PubMed  PubMed Central  Google Scholar 

Kharkwal G, Brami-Cherrier K, Lizardi-Ortiz JE, Nelson AB, Ramos M, Del Barrio D, et al. Parkinsonism driven by antipsychotics originates from dopaminergic control of striatal cholinergic interneurons. Neuron. 2016;91:67–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takeuchi H, Mori Y, Tsutsumi Y. Pathophysiology, prognosis and treatment of tardive dyskinesia. Ther Adv Psychopharmacol. 2022;12:20451253221117310.

Article  PubMed  PubMed Central  Google Scholar 

Loonen AJ, Ivanova SA. New insights into the mechanism of drug-induced dyskinesia. CNS Spectr. 2013;18:15–20.

Article  PubMed  Google Scholar 

Bergman H, Soares-Weiser K. Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018;1:Cd000204.

PubMed  Google Scholar 

Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81:463–9.

Article  PubMed  Google Scholar 

Klawans HL, Rubovits R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry. 1974;37:941–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Greil W, Haag H, Rossnagl G, Rüther E. Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. Br J Psychiatry. 1984;145:304–10.

Article  CAS  PubMed  Google Scholar 

Yassa R. Tardive dyskinesia and anticholinergic drugs. A critical review of the literature. L’Encephale. 1988;14 Spec No:233–9.

CAS  PubMed  Google Scholar 

Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull. 1997;23:583–609.

Article  CAS  PubMed  Google Scholar 

Nishtala PS, Salahudeen MS, Hilmer SN. Anticholinergics: theoretical and clinical overview. Expert Opin Drug Saf. 2016;15:753–68.

Article  CAS  PubMed  Google Scholar 

Barrett MJ, Sargent L, Nawaz H, Weintraub D, Price ET, Willis AW. Antimuscarinic anticholinergic medications in Parkinson disease: to prescribe or deprescribe? Mov Disord Clin Pract. 2021;8:1181–8.

Article  PubMed  PubMed Central  Google Scholar 

Caroff SN, Campbell EC. Drug-induced extrapyramidal syndromes: implications for contemporary practice. Psychiatric Clin North Am. 2016;39:391–411.

Article  Google Scholar 

Caroff SN, Jain R, Morley JF. Revisiting amantadine as a treatment for drug-induced movement disorders. Ann Clin Psychiatry. 2020;32:198–208.

PubMed  Google Scholar 

Bourbeau J, Bhutani M, Hernandez P, Aaron SD, Beauchesne MF, Kermelly SB, et al. 2023 Canadian Thoracic Society guideline on pharmacotherapy in patients with stable COPD. Chest. 2023;164:1159–83.

Article  PubMed  Google Scholar 

Fukuda N, Horita N, Kaneko A, Goto A, Kaneko T, Ota E, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2023;6:CD012066.

PubMed  Google Scholar 

Hsu FC, Weeks CE, Selph SS, Blazina I, Holmes RS, McDonagh MS. Updating the evidence on drugs to treat overactive bladder: a systematic review. Int Urogynecol J. 2019;30:1603–17.

Article  PubMed  PubMed Central  Google Scholar 

Mostafaei H, Salehi-Pourmehr H, Jilch S, Carlin GL, Mori K, Quhal F, et al. Choosing the most efficacious and safe orl teatment for iiopathic oeractive badder: a systematic review and network meta-analysis. Eur Urol Focus. 2022;8:1072–89.

Article  PubMed  Google Scholar 

Gerretsen P, Pollock BG. Drugs with anticholinergic properties: a current perspective on use and safety. Expert Opin Drug Saf. 2011;10:751–65.

Article  PubMed  Google Scholar 

Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384:717–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krystal JH, Kane JM, Correll CU, Walling DP, Leoni M, Duvvuri S, et al. Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet. 2022;400:2210–20.

Article  CAS  PubMed  Google Scholar 

Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. 5th ed. Cambridge: Cambridge University Press; 2021.

Book  Google Scholar 

Dawson AH, Buckley NA. Pharmacological management of anticholinergic delirium - theory, evidence and practice. Br J Clin Pharmacol. 2016;81:516–24.

Article  CAS  PubMed  Google Scholar 

Wang GS, Baker K, Ng P, Janis GC, Leonard J, Mistry RD, et al. A randomized trial comparing physostigmine vs lorazepam for treatment of antimuscarinic (anticholinergic) toxidrome. Clin Toxicol (Phila). 2021;59:698–704.

Article  CAS  PubMed  Google Scholar 

Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62(Suppl 21):11–4.

CAS